EAGAN, Minn.--(BUSINESS WIRE)--Biothera Pharmaceuticals Inc. today will present data on its Phase 2 cancer immunotherapy Imprime PGG, the Company’s first-in-class, systemically administered beta glucan PAMP (Pathogen Associated Molecular Patterning molecule) at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference 2016, taking place at the Moscone Convention Center, San Francisco.
Jeremy Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera will present results demonstrating the ability of Imprime PGG to act as an immunological “ignition switch,” driving a coordinated innate and adaptive immune response to enhance the anti-tumor effects of checkpoint inhibitors (PD-1, PD-L1 antibodies), anti-angiogenic, and tumor-targeting monoclonal antibodies (mAbs). He also will discuss a potential biomarker for Imprime PGG that may enhance patient selection in future clinical trials.
In 2016, the Company expects to initiate clinical trials of combination therapy with Imprime PGG in metastatic melanoma, solid tumors, and hematological malignancies.
Time, Date & Session:
Biomarkers for Cancer Immunotherapy
Imprime PGG – An Advanced, Clinical Stage Pathogen Associated Molecular Pattern (PAMP)
4:00 pm Pacific Time, Thursday, March 10, 2016
About Biothera Pharmaceuticals Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a first-in-class, mid-clinical stage cancer immunotherapy that orchestrates an integrated anti-cancer immune response in combination with checkpoint inhibitors and tumor-targeting and anti-angiogenesis monoclonal antibodies. Imprime PGG has been well-tolerated in trials in over 400 subjects and has established proof of concept in multiple clinical studies, including single-arm and randomized phase 2 studies in non-small cell lung cancer, colorectal cancer, and chronic lymphocytic leukemia.